178 completed. 178 Phase 1, 74 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 178 | Completed 178 |
| Phase 2 | 74 | Completed 74 |
Follow Retinal Degeneration: new trials by email Literature Review of Retinal Degeneration trials Research Report on Retinal Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NT-101 Topical Ophthalmic Solution in Patients With Wet AMD NT-101 Low Dose, NT-101 High Dose - Wet Age Related Macular Degeneration, Wet AMD | Phase 1 / Phase 2 | Completed | NexThera Co., Ltd. | 20 | 2025-03-11 | 2026-05-19 |
| A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324 Faricimab, OLN324 - Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration | Phase 1 | Completed | Ollin Biosciences, Inc. | 164 | 2025-02-12 | 2026-03-19 |
| MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby) VP-001 - Retinitis Pigmentosa 11, Retinal Degeneration | Phase 1 | Completed | PYC Therapeutics | 6 | 2024-06-13 | 2026-05-29 |
| Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy K8 - Geographic Atrophy, Age-Related Macular Degeneration | Phase 1 / Phase 2 | Completed | Inflammasome Therapeutics | 30 | 2024-04-18 | 2026-07-20 |
| A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy BI 771716 - Geographic Atrophy | Phase 1 | Completed | Boehringer Ingelheim | 20 | 2023-10-06 | 2025-02-18 |
| A Study of EXG102-031 in Patients With wAMD (Everest) EXG102-031 - Neovascular (Wet) Age-related Macular Degeneration (nAMD) | Phase 1 | Completed | Exegenesis Bio | 12 | 2023-07-24 | 2026-04-08 |
| A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) Remigromig - Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME) | Phase 1 / Phase 2 | Completed | EyeBiotech Ltd. | 33 | 2023-06-12 | 2026-11-03 |
| SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects VP-001 - Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy | Phase 1 | Completed | PYC Therapeutics | 17 | 2023-04-20 | 2026-05-29 |
| Effect of AIV007 by Periocular Administration in Subjects With Macular Edema Secondary to nAMD and DME AIV007 - Neovascular Age-related Macular Degeneration, Diabetic Macular Edema | Phase 1 | Completed | AiViva BioPharma, Inc. | 19 | 2023-03-02 | 2026-11-04 |
| A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) KIO-301 - Retinitis Pigmentosa, Choroideremia | Phase 1 / Phase 2 | Completed | Kiora Pharmaceuticals, Inc. | 32 | 2022-11-10 | 2026-05-04 |
| Targeted Fluorescence Imaging in AMD Bevacizumab-IRDye800CW - Age-Related Macular Degeneration, NAMD | Phase 1 | Completed | University Medical Center Groningen | 12 | 2022-10-28 | 2024-12-06 |
| Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy Volunteers EB-203, Placebo - Healthy | Phase 1 | Completed | EyebioKorea, Inc. | 28 | 2022-06-29 | 2023-02-23 |
| A Study of Implantation of Retinal Pigment Epithelium in Subjects with Acute Wet Age Related Macular Degeneration PF-05206388 - Age Related Macular Degeneration | Phase 1 | Completed | Moorfields Eye Hospital NHS Foundation Trust | 9 | 2021-10-14 | 2024-11-22 |
| Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMD recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection - Age Related Macular Degeneration | Phase 1 / Phase 2 | Completed | Shanghai Henlius Biotech | 20 | 2021-07-15 | 2023-10-23 |
| ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration ONL1204 Ophthalmic solution, sham injection - Geographic Atrophy | Phase 1 | Completed | ONL Therapeutics | 28 | 2021-07-08 | 2024-11-19 |
| RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration RBM-007 Injectable Solution - Age Related Macular Degeneration | Phase 1 / Phase 2 | Completed | Maturi, Raj K., M.D., P.C. | 5 | 2021-06-15 | 2023-04-12 |
| Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa Intravitreal autologous CD34+ cells - Retinitis Pigmentosa | Phase 1 | Completed | University of California, Davis | 4 | 2021-06-01 | 2024-09-23 |
| QA102 Phase 1 Study in Healthy Young and Older Adult Subjects QA102, Placebo - Age-related Macular Degeneration | Phase 1 | Completed | Smilebiotek Zhuhai Limited | 69 | 2021-05-17 | 2022-01-14 |
| Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops SYL18001 sodium Low dose q.d, SYL18001 sodium Middle dose q.d, SYL18001 sodium High dose q.d - Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers, Choroidal Neovascularization | Phase 1 | Completed | Sylentis, S.A. | 36 | 2021-03-17 | 2022-03-31 |
| This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease tinlarebant - Stargardt Disease | Phase 1 / Phase 2 | Completed | RBP4 Pty Ltd | 13 | 2021-03-12 | 2024-04-12 |
Showing 20 of 178. Sign in to see all of them.
Macular Degeneration (99) · Macular Edema (36) · Retinitis Pigmentosa (25) · Choroidal Neovascularization (19) · Geographic Atrophy (19) · Retinal Diseases (16) · Retinal Vein Occlusion (13) · Eye Diseases (10) · Diabetic Retinopathy (8) · Stargardt Disease (7) · Wet Macular Degeneration (7) · Uveitis (6) · Diabetes Mellitus (5) · Inflammation (3)
Eye Diseases (168) · Retinal Diseases (162) · Macular Degeneration (46) · Eye Diseases, Hereditary (45) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (40) · Genetic Diseases, Inborn (40) · Pathological Conditions, Signs and Symptoms (34) · Uveal Diseases (28) · Pathologic Processes (27) · Retinal Dystrophies (27) · Cardiovascular Diseases (24) · Metaplasia (24) · Vascular Diseases (23) · Choroid Diseases (22)
Ranibizumab (25) · aflibercept (5) · Triamcinolone Acetonide (4) · Vitamin E (3) · pazopanib (3) · retinol acetate (3) · Bevacizumab (2) · Dexamethasone (2) · Laser Therapy (2) · Lutein (2) · Minocycline (2) · Ophthalmic Solutions (2) · Sirolimus (2) · Triamcinolone (2) · Verteporfin (2)
National Eye Institute (NEI) (24) · GlaxoSmithKline (6) · Allergan (5) · Novartis Pharmaceuticals (4) · Astellas Institute for Regenerative Medicine (3) · Genentech, Inc. (3) · Hoffmann-La Roche (3) · Johns Hopkins University (3) · QLT Inc. (3) · University of Sao Paulo (3) · Washington University School of Medicine (3) · Alcon Research (2) · Boehringer Ingelheim (2) · Janssen Research & Development, LLC (2) · Manhattan Eye, Ear & Throat Hospital (2)
United States (128) · United Kingdom (12) · Australia (6) · Brazil (5) · Canada (5) · Puerto Rico (5) · Germany (4) · China (3) · Israel (3) · Japan (3) · Netherlands (3) · France (2) · Latvia (2) · Mexico (2) · New Zealand (2)
Sushanta Mallick (3) · Arshad Khanani, MD (2) · Catherine A Cukras, M.D. (2) · Cathy Sutherland (2) · Peter A Campochiaro, MD (2) · Rubens C Siqueira, MD,PhD (2) · Andrew J Lotery, MD (1) · Andrew R Webster, MD (1)
PMID 22281388, PMID 24113783, PMID 25458728, PMID 39207600, PMID 16759390, PMID 16896916, PMID 17342504, PMID 17963111, PMID 18321465, PMID 18441371, PMID 20169166, PMID 20609706, PMID 21498606, PMID 21546089, PMID 21555610, PMID 22491916, PMID 22775078, PMID 23049090, PMID 23316779, PMID 23361508, PMID 23548622, PMID 23689994, PMID 24053892, PMID 24439297, PMID 24896137, PMID 25001321, PMID 25030840, PMID 25376617, PMID 25525171, PMID 25744334, PMID 26427420, PMID 26431823, PMID 26448901, PMID 26605849, PMID 26656277, PMID 27403996, PMID 27710144, PMID 27820636, PMID 27865764, PMID 28526489, PMID 28570723, PMID 29884405, PMID 30194931, PMID 30196853, PMID 30218651, PMID 31215818, PMID 31805012, PMID 32573764, PMID 33422139, PMID 33469852
2009 (1), 2016 (1), 2017 (1), 2018 (1)